| Name | Title | Contact Details |
|---|
At Ymmunobio, our research is based on our deep understanding of immuno-oncology and precision cancer treatments. We leverage our profound knowledge of biologics, focusing on unique and first-in-class targets while selecting the optimal approach to dev...
Picometrics is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are committed to helping people with severe, chronic cardiovascular diseases realize the promise of patient-specific, expanded multicellular therapy.
Areteia Therapeutics (areteiatx.com) is a clinical stage biotechnology company committed to putting asthma patients in better control of their disease and lives by developing the first potential oral drug for eosinophilic asthma. Areteia`s lead drug candidate is dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences. A syndicate of leading life sciences and strategic investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners, has committed to invest up to $350 million in Series A financing to establish Areteia and advance dexpramipexole through Phase 3 clinical trials, secure commercial supply, and pursue potential next-generation medicines. Areteia will conduct late-stage development including Phase 3 clinical trials of dexpramipexole in partnership with Population Health Partners` development unit, Validae Health.
Yourgene Health, an integrated technologies and services business, enabling the delivery of genomic medicine. Our Expertise: Yourgene has >10 years of experience and expertise in liquid biopsy through NIPT, sample preparation and now precision medicine.